Update on pharmacotherapy for treatment of opioid use disorder

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: VA: American Psychiatric Publishing; 2013.
   Google Scholar
• Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet. 2013;382:1575–1586.
   PubMed Web of Science ®Google Scholar
• Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: results from the 2014 national survey on drug use and health (HHS publication NO. SMA 15-4927, NSDUH series H-50). 2015. [cited 2016 Aug 2]; Available from http://www.samhsa.gov/data
   Google Scholar
• Drug Abuse Warning Network. National estimates of drug-related emergency department visits, 2004-2011. [cited 2016 Aug 2]; Available from http://www.samhsa.gov/data/emergency-department-data-dawn/reports
   Google Scholar
• Oliva EM, Maisel NC, Gordon AJ, et al. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13:374–381.
   PubMed Web of Science ®Google Scholar
• Wejnert C. HIV infection and HIV-associated behaviors among injecting drug users – 20 cities, United States, 2009. MMWR. 2012;61:133–138.
   PubMedGoogle Scholar
• Zibbell JE, Kashif I, Patel RC, et al. Increases in Hepatitis C virus infection related to injection drug use among persons aged ≤30 years – Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR. 2015;64:453–458.
   PubMed Web of Science ®Google Scholar
• McCabe SE, Boyd CJ, Teter CJ. Illicit use of opioid analgesics by high school seniors. J Subst Ab Treat. 2005;28:225–230.
   PubMed Web of Science ®Google Scholar
• Koo DJ, Chitwood DD, Sanchez J. Factors for employment: a case-control study of fully employed and unemployed heroin users. Subst Use Misuse. 2007;42:1035–1054.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevetion (CDC). Vital signs: overdoses of prescription opioid pain relievers - United States, 1999-2008. MMWR. 2011;60:1487–1492.
   PubMedGoogle Scholar
• Dennis BB, Naji L, Bawor M, et al. The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol. Syst Rev. 2014;3:105-4053-3-105.
   Google Scholar
• DeFlavio JR, Rolin SA, Nordstrom BR, et al. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015;15:3019.
   PubMed Web of Science ®Google Scholar
• Cunningham CO, Sohler NL, McCoy K, et al. Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med. 2006;38:336–340.
   PubMed Web of Science ®Google Scholar
• Ward J, Bell J, Mattick RP. Methadone maintenance therapy for opioid dependence: a guide to appropriate use. CNS Drugs. 1996;6:440–449.
   Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3:CD002209.
   PubMed Web of Science ®Google Scholar
• Diaper AM, Law FD, Melichar JK. Pharmacological strategies for detoxification. Br J Clin Pharmacol. 2014;77:302–314.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.
   PubMed Web of Science ®Google Scholar
• Amato L, Davoli M, Minozzi S, et al. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev. 2013;2:CD003409.
   PubMed Web of Science ®Google Scholar
• Senay EC, Dorus W, Thornton W. Withdrawal from methadone maintenance: rate of withdrawal and expectation. Arch Gen Psychiatry. 1977;34:361–367.
   PubMed Web of Science ®Google Scholar
• Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci. 2007;9:455–470.
   PubMedGoogle Scholar
• Ferrari A, Coccia CP, Bertolini A, et al. Methadone – metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004;50:551–559.
   PubMed Web of Science ®Google Scholar
• Kimber J, Larney S, Hickman M, et al. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psych. 2015;2:901–908.
   PubMed Web of Science ®Google Scholar
• Chen LH, Hedegaard H, Warner M. Drug-poisoning deaths involving opioid analgesics: United States, 1999-2011. NCHS Data Brief. 2014;166:1–8.
   PubMedGoogle Scholar
• Kreek MJ. Medical safety and side effects of methadone in tolerant individuals. JAMA. 1973;223:665–668.
   PubMed Web of Science ®Google Scholar
• Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11:S105–S120.
   PubMed Web of Science ®Google Scholar
• Perrin-Terrin A, Pathak A, Lapeyre-Mestre M. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France. Fundam Clin Pharmacol. 2011;25:503–510.
   PubMed Web of Science ®Google Scholar
• Roux P, Lions C, Michel L, et al. Predictors of non-adherence to methadone maintenance treatment in opioid-dependent individuals: implications for clinicians. Curr Pharm Des. 2014;20:4097–4105.
   PubMed Web of Science ®Google Scholar
• Lions C, Carrieri MP, Michel L, et al. Predictors of non-prescribed opioid use after one year of methadone treatment: an attributable-risk approach (ANRS-Methaville trial). Drug Alcohol Depend. 2014;135:1–8.
   PubMed Web of Science ®Google Scholar
• Kidorf M, King VL, Peirce J, et al. Substance use and response to psychiatric treatment in methadone-treated outpatients with comorbid psychiatric disorder. J Subst Abuse Treatment. 2015;51:64–69.
   PubMed Web of Science ®Google Scholar
• Schwartz RP, Jaffe JH, O’Grady KE, et al. Interim methadone treatment: impact on arrests. Drug Alcohol Depend. 2009;103:148–154.
   PubMed Web of Science ®Google Scholar
• Schwartz RP, Kelly SM, O’Grady KE, et al. Interim methadone treatment compared to standard methadone treatment: 4-month findings. J Subst Ab Treat. 2011;41:21–29.
   PubMed Web of Science ®Google Scholar
• Carrieri PM, Michel L, Lions C, et al. Methadone induction in primary care for opioid dependence: a pragmatic randomized trial (ANRS Methaville). PLoS One. 2014;9:e112328.
   PubMed Web of Science ®Google Scholar
• Rashid RA, Kamali K, Habil MH, et al. A mosque-based methadone maintenance treatment strategy: implementation and pilot results. Int J Drug Policy. 2014;25:1071–1075.
   PubMed Web of Science ®Google Scholar
• Jaffray M, Matheson C, Bond CM, et al. Does training in motivational interviewing for community pharmacists improve outcomes for methadone patients? A cluster randomised controlled trial. Int J Pharm Pract. 2014;22:4–12.
   PubMedGoogle Scholar
• Li L, Wu Z, Liang LJ, et al. An intervention targeting service providers and clients for methadone maintenance treatment in China: a cluster-randomized trial. Addiction. 2013;108:356–366.
   PubMed Web of Science ®Google Scholar
• Minozzi S, Amato L, Vecchi S, et al. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev. 2008;2:CD006318.
   PubMed Web of Science ®Google Scholar
• Jones HE, Jansson LM, O’Grady KE, et al. The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicol Teratol. 2013;39:110–115.
   PubMed Web of Science ®Google Scholar
• Gaalema DE, Scott TL, Heil SH, et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction. 2012;107(Suppl 1):53–62.
   PubMed Web of Science ®Google Scholar
• Rich JD, McKenzie M, Larney S, et al. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015;386:350–359.
   PubMed Web of Science ®Google Scholar
• McKenzie M, Zaller N, Dickman SL, et al. A randomized trial of methadone initiation prior to release from incarceration. Substance Abuse. 2012;33:19–29.
   PubMed Web of Science ®Google Scholar
• Wilson ME, Kinlock TW, Gordon MS, et al. Postprison release HIV-risk behaviors in a randomized trial of methadone treatment for prisoners. Am J Addict. 2012;21:476–487.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62:617–627.
   PubMed Web of Science ®Google Scholar
• Brooner RK, King VL, Kidorf M, et al. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54:71–80.
   PubMed Web of Science ®Google Scholar
• Skinner ML, Haggerty KP, Fleming CB, et al. Opiate-addicted parents in methadone treatment: long-term recovery, health, and family relationships. J Addict Dis. 2011;30:17–26.
   PubMed Web of Science ®Google Scholar
• Nunes EV, Quitkin FM, Donovan SJ, et al. Imipramine treatment of opiate-dependent patients with depressive disorders: a placebo-controlled trial. Arch Gen Psychiatry. 1998;55:153–160.
   PubMed Web of Science ®Google Scholar
• Petrakis I, Carroll KM, Nich C, et al. Fluoxetine treatment of depressive disorders in methadone-maintained opiate addicts. Drug Alcohol Depend. 1998;50:221–226.
   PubMed Web of Science ®Google Scholar
• Carpenter KM, Brooks AC, Vosburg SK, et al. The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trial. Drug Alcohol Depend. 2004;74:123–134.
   PubMed Web of Science ®Google Scholar
• Poling J, Pruzinsky R, Kosten TR, et al. Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients. Am J Addict. 2007;16:187–194.
   PubMed Web of Science ®Google Scholar
• Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291:1887–1896.
   PubMed Web of Science ®Google Scholar
• Zarghami M, Sheikhmoonesi F, Ala S, et al. A comparative study of beneficial effects of olanzapine and sodium valproate on aggressive behavior of patients who are on methadone maintenance therapy: a randomized triple blind clinical trial. Eur Rev Med Pharmacol Sci. 2013;17:1073–1081.
   PubMed Web of Science ®Google Scholar
• Stein MD, Kurth ME, Sharkey KM, et al. Trazodone for sleep disturbance during methadone maintenance: a double-blind, placebo-controlled trial. Drug Alcohol Depend. 2012;120:65–73.
   PubMed Web of Science ®Google Scholar
• Xiao L, Tang YL, Smith AK, et al. Nocturnal sleep architecture disturbances in early methadone treatment patients. Psych Res. 2010;179:91–95.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep. 2011;60:537–541.
   PubMedGoogle Scholar
• Page K, Morris MD, Hahn JA, et al. Injection drug use and Hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis. 2013;57(suppl 2):S32–S38.
   PubMed Web of Science ®Google Scholar
• Tsui JI, Evans JL, Lum PJ, et al. Association of opioid agonist therapy with lower incidence of Hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174:1974–1981.
   PubMed Web of Science ®Google Scholar
• Neira-Leon M, Barrio G, Bravo MJ, et al. Infrequent opioid overdose risk reduction behaviors among young adult heroin users in cities with wide coverage of HIV prevention programmes. Int J Drug Policy. 2011;22:16–25.
   PubMed Web of Science ®Google Scholar
• Hopfer CJ, Khuri E, Crowley TJ, et al. Adolescent heroin use: a review of the descriptive and treatment literature. J Subst Ab Treat. 2002;23:231–237.
   PubMed Web of Science ®Google Scholar
• Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev. 2011;12:CD003410.
   PubMed Web of Science ®Google Scholar
• Strang J, Metrebian N, Lintzeras N, et al. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet. 2010;375:1885–1895.
   PubMed Web of Science ®Google Scholar
• Groshkova T, Metrebian N, Hallam C, et al. Treatment expectations and satisfaction of treatment-refractory opioid-dependent patients in RIOTT, the randomised injectable opiate treatment trial, the UK’s first supervised injectable maintenance clinics. Drug Alcohol Rev. 2013;32:566–573.
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, Sordo L, Guh D, et al. Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence. Addict Behav. 2015;41:81–86.
   PubMed Web of Science ®Google Scholar
• Rosenbaum CD, Carreiro SP, Babu KM. Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, salvia divinorum, methoxetamine and piperazines. J Med Toxicol. 2012;8:15–32.
   PubMedGoogle Scholar
• Ulbricht C, Costa D, Dao J, et al. An evidence-based systematic review of kratom (Mitragyna speciose) by the natural standard research collaboration. J Diet Suppl. 2013;10:152–170.
   PubMedGoogle Scholar
• Strain EC, Harrison JA, Bigelow GE. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther. 2011;89:443–449.
   PubMed Web of Science ®Google Scholar
• Middleton LS, Nuzzo PA, Lofwall MR, et al. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction. 2011;106:1460–1473.
   PubMed Web of Science ®Google Scholar
• Jones JD, Madera G, Comer SD. The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users. Pharmacol Biochem Behav. 2014;122:299–306.
   PubMed Web of Science ®Google Scholar
• Lintzeris N, Leung SY, Dunlop AJ, et al. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Drug Alcohol Depend. 2013;131:119–126.
   PubMed Web of Science ®Google Scholar
• Press announcements > FDA approves first buprenorphine implant for treatment of opioid dependence. [ cited: 14/sep/2016] Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503719.htm
   Google Scholar
• Rosenthal RN, Ling W, Casadonte P, et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction. 2013;108:2141–2149.
   PubMed Web of Science ®Google Scholar
• Ling W, Hillhouse M, Domier C, et al. Buprenorphine tapering schedule and illicit opioid use. Addiction. 2009;104:256–265.
   PubMed Web of Science ®Google Scholar
• Dunn KE, Saulsgiver KA, Miller ME, et al. Characterizing opioid withdrawal during double-blind buprenorphine detoxification. Drug Alcohol Depend. 2015;151:47–55.
   PubMed Web of Science ®Google Scholar
• Hillhouse M, Domier CP, Chim D, et al. Provision of ancillary medications during buprenorphine detoxification does not improve treatment outcomes. J Addict Dis. 2010;29:23–29.
   PubMed Web of Science ®Google Scholar
• Sigmon SC, Dunn KE, Badger GJ, et al. Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study. Addict Behav. 2009;34:304–311.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Schottenfeld RS, Cutter CJ, et al. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174:1947–1954.
   PubMed Web of Science ®Google Scholar
• Soeffing JM, Martin LD, Fingerhood MI, et al. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Ab Treat. 2009;37:426–430.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict. 2008;17:116–120.
   PubMed Web of Science ®Google Scholar
• Jacobs P, Ang A, Hillhouse MP, et al. Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories. Am J Addict. 2015;24:667–675.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Hillhouse M, Thomas C, et al. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J Addict Med. 2013;7:33–38.
   PubMed Web of Science ®Google Scholar
• Mitchell SG, Gryczynski J, Schwartz RP, et al. A randomized trial of intensive outpatient (IOP) vs.standard outpatient (OP) buprenorphine treatment for African Americans. Drug Alcohol Depend. 2013;128:222–229.
   PubMed Web of Science ®Google Scholar
• Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320–2331.
   PubMed Web of Science ®Google Scholar
• Lacroix I, Berrebi A, Garipuy D, et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol. 2011;67:1053–1059.
   PubMed Web of Science ®Google Scholar
• Bandstra ES. Maternal Opioid Treatment: Human Experimental Research (MOTHER) study: maternal, fetal and neonatal outcomes from secondary analyses. Addiction. 2012;107(Suppl 1):1–4.
   PubMed Web of Science ®Google Scholar
• Gold MS, Pottash AC. The neurobiological implications of clonidine HCl. Ann NY Acad Sci. 1981;362:191–202.
   PubMedGoogle Scholar
• Gowing L, Farrell M, Ali R, et al. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2016;5:CD002024.
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Johnson RE, Kocher TR. Clonidine in morphine withdrawal. differential effects on signs and symptoms. Arch Gen Psychiatry. 1985;42(11):1063–1066.
   PubMed Web of Science ®Google Scholar
• Ling W, Amass L, Shoptaw S, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid, detoxification: findings from the national institute on drug abuse clinical trials network. Addiction. 2005;100(8):1090–1100.
   PubMed Web of Science ®Google Scholar
• Charney DS, Sternberg DE, Kleber HD, et al. The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. Arch Gen Psychiatry. 1981;38(11):1273–1277.
   PubMed Web of Science ®Google Scholar
• Gowing L, Farrell MF, Ali R, et al. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2014;3:CD002024.
   PubMed Web of Science ®Google Scholar
• Washton AM, Resnick RB. Clonidine for opiate detoxification: outpatient clinical trials. Am J Psych. 1980;137:1121–1122.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Wang GB, Zhao LY, et al. Clonidine improved laboratory-measured decision-making performance in abstinent heroin addicts. PLoS One. 2012;7:e29084.
   PubMed Web of Science ®Google Scholar
• Kowalczyk WJ, Phillips KA, Jobes ML, et al. Clonidine maintenance prolongs opioid abstinence and decouples stress from craving in daily life: a randomized controlled trial with ecological momentary assessment. Am J Psych. 2015;172:760–767.
   PubMed Web of Science ®Google Scholar
• Rosenberg H, Melville J, McLean PC. Acceptability and availability of pharmacological interventions for substance misuse by British NHS treatment services. Addition. 2002;97:59–65.
   Web of Science ®Google Scholar
• Carnwath T, Hardman J. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend. 1998;50:251–254.
   PubMed Web of Science ®Google Scholar
• Gish EC, Miller JL, Honey BL, et al. Lofexidine, an α2-receptor agonist for opioid detoxification. Ann Pharmacother. 2010;44:343–351.
   PubMed Web of Science ®Google Scholar
• Preston KL, Bigelow GE. Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther. 1993;264:813–823.
   PubMed Web of Science ®Google Scholar
• Kleber HD. Naltrexone. J Subst Abuse Treat. 1985;2:117–122.
   PubMedGoogle Scholar
• Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;4:CD001333.
   PubMedGoogle Scholar
• Miotto K, McCann M, Basch J, et al. Naltrexone and dysphoria: fact or myth? Am J Addict. 2002;11:151–160.
   PubMed Web of Science ®Google Scholar
• Dean AJ, Saunders JB, Jones RT, et al. Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. J Psychiatry Neurosci. 2006;31:38–45.
   PubMed Web of Science ®Google Scholar
• Dunn K, DeFulio A, Everly JJ, et al. Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes. Psychol Addict Behav. 2015;29:270–276.
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep. 2010;12:448–453.
   PubMed Web of Science ®Google Scholar
• Bigelow GE, Preston KL, Schmittner J, et al. Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course. Drug Alcohol Depend. 2012;123:57–65.
   PubMed Web of Science ®Google Scholar
• Sullivan MA, Bisaga A, Mariani JJ, et al. Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade? Drug Alcohol Depend. 2013;133:80–85.
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Zvartau E, Blokhina E, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psych. 2012;69:973–981.
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108:1628–1637.
   PubMed Web of Science ®Google Scholar
• Mitchell MC, Memisoglu A, Silverman BL. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. J Stud Alcohol Drugs. 2012;73:991–997.
   PubMed Web of Science ®Google Scholar
• Vagenas P, Di Paola A, Herme M, et al. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. J Subst Ab Treat. 2014;47:35–40.
   PubMed Web of Science ®Google Scholar
• Nunes EV, Krupitsky E, Ling W, et al. Treating opioid dependence with injectable extended-release naltrexone (XR-NTX): who will respond? J Addict Med. 2015;9:238–243.
   PubMed Web of Science ®Google Scholar
• Lee JD, Friedmann PD, Boney TY, et al. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial. Contemp Clin Trials. 2015;41:110–117.
   PubMed Web of Science ®Google Scholar
• Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374:1232–1242.
   PubMed Web of Science ®Google Scholar
• Leslie DL, Milchak W, Gastfriend DR, et al. Effects of injectable extended-release naltrexone (XR-NTX) for opioid dependence on residential rehabilitation outcomes and early follow-up. Am J Addict. 2015;24:265–270.
   PubMed Web of Science ®Google Scholar
• Kunoe N, Lobmaier P, Vederhus JK, et al. Challenges to antagonist blockade during sustained-release naltrexone treatment. Addiction. 2010;105:1633–1639.
   PubMed Web of Science ®Google Scholar
• Mannelli P, Wu LT, Peindl KS, et al. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial. Drug Alcohol Depend. 2014;138:83–88.
   PubMed Web of Science ®Google Scholar
• Hulse GK, Morris N, Arnold-Reed D, et al. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psych. 2009;66:1108–1115.
   PubMed Web of Science ®Google Scholar
• Hulse GK, Ngo HT, Tait RJ. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone. Biol Psych. 2010;68:296–302.
   PubMed Web of Science ®Google Scholar
• Kunoe N, Lobmaier P, Vederhus JK, et al. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psych. 2009;194:541–546.
   PubMed Web of Science ®Google Scholar
• Mannelli P, Patkar AA, Peindl K, et al. Early outcomes following low dose naltrexone enhancement of opioid detoxification. Am J Addict. 2009;18:109–116.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Krupitsky E, Verbitskaya E, et al. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psych. 2012;169:531–536.
   PubMed Web of Science ®Google Scholar